CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES ›› 2020, Vol. 38 ›› Issue (3): 370-377.doi: 10.12140/j.issn.1000-7423.2020.03.018

• REVIEWS • Previous Articles     Next Articles

Research progress on combined medications for schistosomiasis

ZHAO Jin-ying1, LIU Peng2, LI Yan-wei1,2, WANG Shi-ping3,*()   

  1. 1 Key Laboratory of Molecular Biology Diagnosis, Shaoyang University, Shaoyang 422000, China
    2 Department of Human Anatomy and Histology and Embryology, Basic Medical College, Shaoyang College, Shaoyang 422000, China
    3 Department of Pathogenic Biology, Xiangya School of Medicine, Central South University, Changsha 410013, China
  • Received:2019-08-16 Online:2020-06-30 Published:2020-07-07
  • Contact: Shi-ping WANG E-mail:wsp4373383@126.com
  • Supported by:
    Research Project of the Education Department of Hunan Province(16C1439)

Abstract:

Currently, the praziquantel (PZQ) remains the drug of choice for schistosomiasis treatment. Despite its effectiveness in killing adult schistosomes, PZQ is ineffective for schistosomula, and monotherapy using PZQ cannot reverse the pathological damage associated with the infection. With the emerging PZQ-resistant strains, it is imperative to find out alternatives for PZQ. At present, the research and development of new anti-schistosomiasis drugs is moving slowly, but pre-clinical and clinical trials found that combined medication of PZQ and various antimalarial drugs has shown good schistosomicidal effects. Also, synergistic effects have been exerted by combined use of PZQ and auxiliary drugs in the treatment of schistosomiasis. This article provides a review on the research progress in this field.

Key words: Schistosomiasis, Praziquantel, Antimalarials, Anti-fibrosis, Antioxidants

CLC Number: